Research in Oncology and rDNA

Research in Oncology 2017-05-26T20:38:41+00:00
Every year, nearly 14 million people around the world learn that they have cancer. Another 8 million people die from the disease (according to the Centers for Disease Control).

To help in the mission to find a cure, the WIRB-Copernicus Group® (WCG) has created WCG Oncology, a comprehensive solution to enable the highest quality review of cancer research and to ensure the safety of its participants.

Through our access to WCG Oncology, Midlands IRB is able to provide a deeper level of support to researchers around the world in their mission to eradicate cancer.

THE THREE FACETS OF WCG ONCOLOGY INCLUDE:

An Advisory Board of Visionaries and thought-leaders in oncology to provide WCG with guidance and strategic counsel on the changing landscape of research in oncology.

GEORGE DEMETRI, MD
Dana-Farber Cancer Institute

JOHN M. FALLETTA, MD
Duke University Medical Center

ARNOLD J. LEVINE, PHD
Institute for Advanced Study, School of Natural Sciences

JOHN E. NIEDERHUBER, MD
Inova Translational Medicine Institute;
Former Head of the National Cancer Institute

JAMES ROTHMAN, PHD
Yale University; Recipient, Nobel Prize in Medicine, 2013

HOWARD SCHER, MD
Memorial Sloan Kettering Cancer Center

A PANEL OF EXPERT CONSULTANTS, each of whom is deeply knowledgeable in a specific oncological discipline or area of research, to assist in the review of complex and scientifically challenging research.

3 DEDICATED, EXPERIENCED REVIEW PANELS focused wholly on the ethical and regulatory oversight of research in oncology.